Valuation Charles River Laboratories International, Inc.
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 233.41 USD | -0.08% |
|
+1.18% | +17.01% |
Company Valuation: Charles River Laboratories International, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 18,941 | 11,138 | 12,252 | 9,520 | 10,023 | 11,243 | - | - |
| Change | - | -41.2% | 10% | -22.3% | 5.29% | 12.17% | - | - |
| Enterprise Value (EV) 1 | 21,366 | 13,616 | 14,622 | 11,565 | 11,946 | 13,056 | 12,630 | 12,250 |
| Change | - | -36.28% | 7.39% | -20.91% | 3.29% | 9.3% | -3.27% | -3.01% |
| P/E | 49.4x | 23.1x | 25.9x | 931x | -70x | 38x | 25.5x | 23.4x |
| PBR | 7.45x | 3.75x | 3.41x | 2.75x | 3.17x | 3.41x | 3.05x | 2.77x |
| PEG | - | 0.9x | -9.44x | -9.5x | 0x | -0x | 0.5x | 2.71x |
| Capitalization / Revenue | 5.35x | 2.8x | 2.97x | 2.35x | 2.5x | 2.92x | 2.87x | 2.74x |
| EV / Revenue | 6.04x | 3.42x | 3.54x | 2.86x | 2.98x | 3.39x | 3.22x | 2.99x |
| EV / EBITDA | 24.3x | 13.7x | 14.4x | 11.6x | 12.3x | 13.2x | 12x | 10.9x |
| EV / EBIT | 28.8x | 16.3x | 17.4x | 14.3x | 15x | 16x | 14.3x | 12.9x |
| EV / FCF | 40.2x | 46.2x | 40x | 23.1x | 23x | 33.7x | 29.1x | 38.9x |
| FCF Yield | 2.49% | 2.17% | 2.5% | 4.34% | 4.34% | 2.96% | 3.43% | 2.57% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 7.6 | 9.48 | 9.22 | 0.2 | -2.91 | 6.135 | 9.169 | 9.961 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 | 3,851 | 3,922 | 4,097 |
| EBITDA 1 | 879.5 | 990.9 | 1,013 | 996.1 | 971.5 | 990.4 | 1,051 | 1,119 |
| EBIT 1 | 742.1 | 834 | 838.8 | 805.9 | 793.9 | 814.5 | 883.7 | 949.7 |
| Net income 1 | 391 | 486.2 | 474.6 | 10.3 | -144.3 | 285.1 | 417.3 | 447 |
| Net Debt 1 | 2,425 | 2,477 | 2,370 | 2,046 | 1,923 | 1,814 | 1,387 | 1,007 |
| Reference price 2 | 375.34 | 218.92 | 238.84 | 186.16 | 203.66 | 233.41 | 233.41 | 233.41 |
| Nbr of stocks (in thousands) | 50,464 | 50,879 | 51,297 | 51,136 | 49,215 | 48,168 | - | - |
| Announcement Date | 2/16/22 | 2/22/23 | 2/14/24 | 2/19/25 | 2/18/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 38.05x | 3.39x | 13.18x | -.--% | 11.24B | |
| 35.38x | 6.18x | 19.12x | 0.93% | 50.73B | |
| -23.4x | 342.07x | -22.1x | -.--% | 39.73B | |
| 25.29x | 2.8x | 12.09x | -.--% | 34.69B | |
| 45.73x | 4.51x | 28.9x | -.--% | 33.21B | |
| 27.05x | 7.93x | 19.91x | 0.42% | 26.76B | |
| 31.75x | 5.12x | 23.32x | -.--% | 15.37B | |
| 23.95x | 2.04x | 8.96x | 1.12% | 13.78B | |
| 23.74x | 1.89x | 11.45x | -.--% | 12.85B | |
| Average | 25.28x | 41.77x | 12.76x | 0.27% | 26.48B | |
| Weighted average by Cap. | 23.22x | 60.97x | 11.67x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CRL Stock
- Valuation Charles River Laboratories International, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
